Home » Stocks » Lipocine

Lipocine Inc. (LPCN)

Stock Price: $1.33 USD -0.03 (-2.21%)
Updated Oct 21, 2020 4:00 PM EDT - Market closed
After-hours: $1.30 -0.03 (-2.26%) Oct 21, 7:59 PM

Stock Price Chart

Key Info

Market Cap 87.36M
Revenue (ttm) 164,990
Net Income (ttm) -18.49M
Shares Out 65.69M
EPS (ttm) -0.51
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Oct 21, 2020
Last Price $1.33
Previous Close $1.36
Change ($) -0.03
Change (%) -2.21%
Day's Open 1.35
Day's Range 1.30 - 1.36
Day's Volume 591,771
52-Week Range 0.30 - 3.11

More Stats

Market Cap 87.36M
Enterprise Value 70.39M
Earnings Date (est) Nov 4, 2020
Ex-Dividend Date n/a
Shares Outstanding 65.69M
Float 63.91M
EPS (basic) -0.49
EPS (diluted) -0.51
FCF / Share -0.27
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 4.27M
Short Ratio 1.51
Short % of Float 6.69%
Beta 0.48
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio 529.49
PB Ratio 6.93
Revenue 164,990
Operating Income -15.24M
Net Income -18.49M
Free Cash Flow -13.56M
Net Cash 16.97M
Net Cash / Share 0.26
Gross Margin -3,063.03%
Operating Margin -9,239.33%
Profit Margin -11,208.30%
FCF Margin -8,219.24%
ROA -44.15%
ROE -161.26%
ROIC -294.60%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (2)

Buy 1
Overweight 0
Hold 1
Underweight 0
Sell 0

Analyst Consensus: Overweight

Price Target

(125.56% upside)
Current: $1.33
Target: 3.00
*Average 12-month price target from 2 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Revenue Growth-61.45%--------
Gross Profit0.160.43-----7.71-
Operating Income-12.90-11.33-21.22-19.19-18.38-20.48-10.683.88-0.01
Net Income-13.01-11.66-20.98-18.97-18.21-20.37-10.593.89-0.01
Shares Outstanding25.8821.3520.0518.2616.4712.777.364.461.80
Earnings Per Share-0.50-0.55-1.05-1.04-1.11-1.60-1.440.85-
Operating Cash Flow-11.67-12.08-16.70-18.28-15.36-17.30-8.59-3.18-0.01
Capital Expenditures----0.06-0.03-0.06--0.01-
Free Cash Flow-11.67-12.08-16.70-18.34-15.38-17.36-8.59-3.19-0.01
Cash & Equivalents19.0720.2521.4726.8444.3827.6745.265.380.02
Total Debt7.1510.26-------
Net Cash / Debt11.929.9921.4726.8444.3827.6745.265.380.02
Book Value6.299.4318.9826.0241.9926.3644.825.320.02
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Lipocine Inc.
Country United States
Employees 12
CEO Mahesh V. Patel

Stock Information

Ticker Symbol LPCN
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: LPCN


Lipocine, a specialty pharmaceutical company, focuses on the development of pharmaceutical products in the area of men's and women's health. Its primary development programs are based on oral delivery solutions for poorly bioavailable drugs. The company has a portfolio of product candidates designed to produce pharmacokinetic characteristics and facilitate lower dosing requirements, bypass first-pass metabolism in certain cases, reduce side effects, and eliminate gastrointestinal interactions that limit bioavailability. Its lead product candidate is TLANDO, an oral testosterone replacement therapy. The company's pipeline candidates also include LPCN 1111, an oral testosterone therapy product for once daily dosing that completed Phase II testing; LPCN 1107, an oral hydroxyprogesterone caproate product for the prevention of recurrent preterm birth and has completed an end-of-Phase II meeting with the Food and Drug Administration; and LPCN 1144, an oral prodrug of bioidentical testosterone that is in Phase I Clinical trial for the treatment of non-alcoholic steatohepatitis. Lipocine Inc. is headquartered in Salt Lake City, Utah.